tamoxifen

(redirected from Tamoxifen citrate)
Also found in: Dictionary, Thesaurus, Medical.

tamoxifen

(təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancerbreast cancer,
cancer that originates in the breast. Breast cancer is the second leading cause of cancer death in women (following lung cancer). Although the vast majority of the cases occur in women, some men also get breast cancer.
..... Click the link for more information.
. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors and to control metastatic breast cancer. In breast tissue, tamoxifen blocks the effect of estrogen on cancerous cells that need estrogen to grow; not all breast cancers are affected by tamoxifen and other selective estrogen receptor modulators. In postmenopausal women with breast cancer, aromatase inhibitors, which block the production of estrogen outside the ovaries, are typically used instead of tamoxifen. In 1998, a large study of healthy women at high risk for breast cancer showed that tamoxifen can also prevent first occurrence of the disease; women who took the drug had a 45% lower incidence of cancer that those who received a placebo, and tamoxifen is now also used to reduce the risk of breast cancer in high risk patients. Adverse effects include and increased risk of uterine and endometrial cancer, blood clots, stroke, and cataracts.
The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/
Mentioned in ?
References in periodicals archive ?
In reviewing this FTC study and the concession made by the majority in Tamoxifen, the court explained, "reverse payments enable the holder of a patent that the holder knows is weak to buy its way out of both competition with the challenging competitor and possible invalidation of the patent." 686 F.3d at 215 (citing In re Tamoxifen Citrate Antitrust Litig., 466 F.3d 187, 211 (2d Cir.
Although it is well demonstrated that xenobiotics induces the activities of drug metabolizing enzymes, the effect of tamoxifen citrate on xanthine oxidase activity during carcinogenesis is still sporadic.
Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection), PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide, and SOLTAMOX(TM) (tamoxifen citrate, oral solution 10mg/5mL) in the United States.
In 1993, as a result of a patent challenge, Barr and AstraZeneca entered into an agreement that resulted in the distribution by Barr of a more affordable version of AstraZeneca's Nolvadex (Tamoxifen Citrate) treatment for breast cancer.
Tamoxifen citrate is manufactured by the ICI Pharma company of Wilmington, Del.
Stuart Pharmaceuticals' tamoxifen citrate, has been shown to decrease the rate of cancer spread and death in postmenopausal women whose breat cancer cells depend on the hormone estrogen for growth.
Soltamox (tamoxifen citrate) oral liquid solution is the only liquid form of tamoxifen that is used for the treatment and prevention of breast cancer.
Barr joined the case as a plaintiff with the position that its damages were similar to AstraZeneca's because four out of five breast cancer patients now use tamoxifen citrate, of which Barr is a distributor.
According to the agreement and a shared sales force agreement with Mission, in addition to promoting Dara's products Soltamox (tamoxifen citrate), Gelclair and Bionect, the Alamo sales team will also carry three Mission Pharmacal products: Ferralet 90 (for anemia), BINOSTO (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis), and Aquoral (for chemotherapy/radiation therapy-induced dry mouth).
Zeneca noted that Evista's approval by the Food and Drug Administration is only for the prevention of osteoporosis and claims that Nolvadex (tamoxifen citrate), patented by Zeneca, is the only drug proven effective for reducing breast cancer.
The company revealed that it has introduced its second product in five months (Soltamox, the only FDA-approved oral liquid version of tamoxifen citrate) and plans to introduce its third product in Q1 2013.